Direct thrombin inhibitor
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Direct thrombin inhibitors (DTIs) are a class of medication that act as anticoagulants (delaying blood clotting) by directly inhibiting the enzyme thrombin. Some are in clinical use, while others are undergoing clinical development. Several members of the class are expected to replace heparin (and derivatives) and warfarin in various clinical scenarios.
Types
There are two types of DTIs, dependent on their interaction with the thrombin molecule. Bivalent DTIs (hirudin and analogs) bind both to the active site and exosite 1, while univalent DTIs bind only to the active site.[1]
Bivalent
Hirudin and derivatives were originally discovered in Hirudo medicinalis:
- Hirudin
- Bivalirudin (transient inhibition - is cleaved by thrombin)
- Lepirudin
- Desirudin
Univalent
Univalent DTIs include:
- Argatroban
- Melagatran (and its prodrug ximelagatran)
- Dabigatran
Uses
Bivalent DTIs enjoy limited use in circumstances where heparin would be indicated but cannot be used, such as the acute coronary syndrome ("unstable angina"). As they are administered by injection (intravenous, intramuscular or subcutaneous), they are less suitable for long-term treatment.[1]
Argatroban (as well as the hirudins) are used for heparin-induced thrombocytopenia, a rare but serious complication of heparin treatment that requires anticoagulation (as it increases both arterial and venous thrombosis risk) but not with the putative agent, heparin.[1]
Ximelagatran showed good efficacy compared with warfarin in several trials in prevention and treatment of deep vein thrombosis and as thromboprophylaxis in atrial fibrillation.[1] Development was stopped by manufacturer AstraZeneca, however, because of reports of liver enzyme derangements and liver failure.[2] Dabigatran is under development for similar indications.
Monitoring
There is no therapeutic drug monitoring widely available for DTIs, in contrast with warfarin (INR) and heparin (APTT). The ecarin clotting time, although not in general clinical use, would be the most appropriate monitoring test.[1]
Reference
- ↑ 1.0 1.1 1.2 1.3 1.4 Di Nisio M, Middeldorp S, Büller H (2005). "Direct thrombin inhibitors.". N Engl J Med 353 (10): 1028-40. PMID 16148288.
- ↑ AstraZeneca (February 14, 2006). AstraZeneca Decides to Withdraw Exanta. Press release.
WikiDoc Research Resources for Direct thrombin inhibitor | |
|---|---|
| Articles on Direct thrombin inhibitor | Most recent articles on Direct thrombin inhibitor • Most cited articles on Direct thrombin inhibitor • Review articles on Direct thrombin inhibitor • Articles on Direct thrombin inhibitor in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Direct thrombin inhibitor | Powerpoint slides on Direct thrombin inhibitor • Images of Direct thrombin inhibitor • Photos of Direct thrombin inhibitor • Podcasts & MP3s on Direct thrombin inhibitor • Videos on Direct thrombin inhibitor |
| Evidence Based Medicine Regarding Direct thrombin inhibitor | Cochrane Collaboration on Direct thrombin inhibitor • Bandolier on Direct thrombin inhibitor • TRIP on Direct thrombin inhibitor |
| Cost Effectiveness of Direct thrombin inhibitor | Cost Effectiveness of Direct thrombin inhibitor |
| Clinical Trials Involving Direct thrombin inhibitor | Ongoing Trials on Direct thrombin inhibitor at Clinical Trials.gov • Trial results on Direct thrombin inhibitor • Clinical Trials on Direct thrombin inhibitor at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Direct thrombin inhibitor | US National Guidelines Clearinghouse on Direct thrombin inhibitor • NICE Guidance on Direct thrombin inhibitor • NHS PRODIGY Guidance • FDA on Direct thrombin inhibitor • CDC on Direct thrombin inhibitor |
| Textbook Information on Direct thrombin inhibitor | Books and Textbook Information on Direct thrombin inhibitor |
| Pharmacology Resources on Direct thrombin inhibitor | Dosing of Direct thrombin inhibitor • Drug interactions with Direct thrombin inhibitor • Side effects of Direct thrombin inhibitor • Allergic reactions to Direct thrombin inhibitor • Overdose information on Direct thrombin inhibitor • Carcinogenicity information on Direct thrombin inhibitor • Direct thrombin inhibitor in pregnancy • Pharmacokinetics of Direct thrombin inhibitor • |
| Genetics, Pharmacogenomics, and Proteinomics of Direct thrombin inhibitor | Genetics of Direct thrombin inhibitor • Pharmacogenomics of Direct thrombin inhibitor • Proteomics of Direct thrombin inhibitor |
| Newstories on Direct thrombin inhibitor | Direct thrombin inhibitor in the news • Be alerted to news on Direct thrombin inhibitor • News trends on Direct thrombin inhibitor |
| Commentary on Direct thrombin inhibitor | Blogs on Direct thrombin inhibitor |
| Patient Resources on Direct thrombin inhibitor | Patient resources on Direct thrombin inhibitor • Discussion groups on Direct thrombin inhibitor • Patient Handouts on Direct thrombin inhibitor • Directions to Hospitals Treating Direct thrombin inhibitor • Risk calculators and risk factors for Direct thrombin inhibitor |
| Healthcare Provider Resources on Direct thrombin inhibitor | Symptoms of Direct thrombin inhibitor • Causes & Risk Factors for Direct thrombin inhibitor • Diagnostic studies for Direct thrombin inhibitor • Treatment of Direct thrombin inhibitor |
| Continuing Medical Education (CME) Programs on Direct thrombin inhibitor | CME Programs on Direct thrombin inhibitor |
| International Resources on Direct thrombin inhibitor | Direct thrombin inhibitor en Espanol • Direct thrombin inhibitor en Francais |
| Business Resources on Direct thrombin inhibitor | Direct thrombin inhibitor in the Marketplace • Patents on Direct thrombin inhibitor |
| Informatics Resources on Direct thrombin inhibitor | List of terms related to Direct thrombin inhibitor |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
